Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan

Fuu Jen Tsai, Chi Fung Cheng, Chao Jung Chen, Chih Ying Lin, Yi Fang Wu, Te Mao Li, Po Heng Chuang, Yang Chang Wu, Chih Ho Lai, Xiang Liu, Hsinyi Tsang, Ting Hsu Lin, Chiu Chu Liao, Shao Mei Huang, Ju Pi Li, Jung Chun Lin, Chih Chien Lin, Wen Miin Liang, Ying Ju Lin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Chinese herbal medicine (CHM) is a complementary natural medicine that is used widely for the treatment of hepatic diseases. The aim of this study was to investigate the effects of the long-term use of CHM for the treatment of liver diseases, as prescribed by TCM doctors, on overall mortality and hepatic outcomes in patients with HCV. Patients and methods: We identified 98788 patients with HCV. Of these, 829 and 829 patients who were users and non-users of CHM, respectively, were matched for age, gender, CCI, and comorbidities prior to CHM treatment. The chi-squared test, Cox proportional hazard model, Kaplan–Meier method, and log-rank test were used for comparisons. Results: CHM users had a lower risk of overall mortality than non-users after adjustment for comorbidities by using a multivariate Cox proportional hazard model (p-value < 0.001; HR: 0.12, 95% CI: 0.06–0.26). In addition,the CHM users had a lower risk of liver cirrhosis than non-users after adjustment for comorbidities (p-value = 0.028; HR: 0.29, 95% CI: 0.09–0.88). The 12-year cumulative incidences of overall mortality and liver cirrhosis were lower in the CHM group (p-value < 0.05 for both, log rank test). The CHM co-prescription for Dan-Shen, Bie-Jia, Jia-Wei-Xiao-Yao-San => E-Shu was found to occur most often associated for the specific treatment of HCV infection. Conclusion: CHM as adjunctive therapy may reduce the overall mortality and the risk of liver cirrhosis in patients with HCV. The comprehensive list of the herbal medicines that may be used for the treatment of patients with HCV may be useful in future scientific investigations or for future therapeutic interventions to prevent negative hepatic outcomes in patients with HCV.

Original languageEnglish
Pages (from-to)30-38
Number of pages9
JournalPhytomedicine
Volume57
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Phytotherapy
Herbal Medicine
Virus Diseases
Taiwan
Hepacivirus
Survival
Liver
Proportional Hazards Models
Therapeutics
Mortality
Comorbidity
Complementary Therapies
Liver Cirrhosis
Liver Diseases
Infection

Keywords

  • Chinese herbal medicine
  • HCV
  • Liver cirrhosis
  • Overall mortality

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine

Cite this

Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. / Tsai, Fuu Jen; Cheng, Chi Fung; Chen, Chao Jung; Lin, Chih Ying; Wu, Yi Fang; Li, Te Mao; Chuang, Po Heng; Wu, Yang Chang; Lai, Chih Ho; Liu, Xiang; Tsang, Hsinyi; Lin, Ting Hsu; Liao, Chiu Chu; Huang, Shao Mei; Li, Ju Pi; Lin, Jung Chun; Lin, Chih Chien; Liang, Wen Miin; Lin, Ying Ju.

In: Phytomedicine, Vol. 57, 01.04.2019, p. 30-38.

Research output: Contribution to journalArticle

Tsai, FJ, Cheng, CF, Chen, CJ, Lin, CY, Wu, YF, Li, TM, Chuang, PH, Wu, YC, Lai, CH, Liu, X, Tsang, H, Lin, TH, Liao, CC, Huang, SM, Li, JP, Lin, JC, Lin, CC, Liang, WM & Lin, YJ 2019, 'Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan', Phytomedicine, vol. 57, pp. 30-38. https://doi.org/10.1016/j.phymed.2018.09.237
Tsai, Fuu Jen ; Cheng, Chi Fung ; Chen, Chao Jung ; Lin, Chih Ying ; Wu, Yi Fang ; Li, Te Mao ; Chuang, Po Heng ; Wu, Yang Chang ; Lai, Chih Ho ; Liu, Xiang ; Tsang, Hsinyi ; Lin, Ting Hsu ; Liao, Chiu Chu ; Huang, Shao Mei ; Li, Ju Pi ; Lin, Jung Chun ; Lin, Chih Chien ; Liang, Wen Miin ; Lin, Ying Ju. / Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. In: Phytomedicine. 2019 ; Vol. 57. pp. 30-38.
@article{055ba10e2a774def89ec220b4763855d,
title = "Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan",
abstract = "Background: Chinese herbal medicine (CHM) is a complementary natural medicine that is used widely for the treatment of hepatic diseases. The aim of this study was to investigate the effects of the long-term use of CHM for the treatment of liver diseases, as prescribed by TCM doctors, on overall mortality and hepatic outcomes in patients with HCV. Patients and methods: We identified 98788 patients with HCV. Of these, 829 and 829 patients who were users and non-users of CHM, respectively, were matched for age, gender, CCI, and comorbidities prior to CHM treatment. The chi-squared test, Cox proportional hazard model, Kaplan–Meier method, and log-rank test were used for comparisons. Results: CHM users had a lower risk of overall mortality than non-users after adjustment for comorbidities by using a multivariate Cox proportional hazard model (p-value < 0.001; HR: 0.12, 95{\%} CI: 0.06–0.26). In addition,the CHM users had a lower risk of liver cirrhosis than non-users after adjustment for comorbidities (p-value = 0.028; HR: 0.29, 95{\%} CI: 0.09–0.88). The 12-year cumulative incidences of overall mortality and liver cirrhosis were lower in the CHM group (p-value < 0.05 for both, log rank test). The CHM co-prescription for Dan-Shen, Bie-Jia, Jia-Wei-Xiao-Yao-San => E-Shu was found to occur most often associated for the specific treatment of HCV infection. Conclusion: CHM as adjunctive therapy may reduce the overall mortality and the risk of liver cirrhosis in patients with HCV. The comprehensive list of the herbal medicines that may be used for the treatment of patients with HCV may be useful in future scientific investigations or for future therapeutic interventions to prevent negative hepatic outcomes in patients with HCV.",
keywords = "Chinese herbal medicine, HCV, Liver cirrhosis, Overall mortality",
author = "Tsai, {Fuu Jen} and Cheng, {Chi Fung} and Chen, {Chao Jung} and Lin, {Chih Ying} and Wu, {Yi Fang} and Li, {Te Mao} and Chuang, {Po Heng} and Wu, {Yang Chang} and Lai, {Chih Ho} and Xiang Liu and Hsinyi Tsang and Lin, {Ting Hsu} and Liao, {Chiu Chu} and Huang, {Shao Mei} and Li, {Ju Pi} and Lin, {Jung Chun} and Lin, {Chih Chien} and Liang, {Wen Miin} and Lin, {Ying Ju}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.phymed.2018.09.237",
language = "English",
volume = "57",
pages = "30--38",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",

}

TY - JOUR

T1 - Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan

AU - Tsai, Fuu Jen

AU - Cheng, Chi Fung

AU - Chen, Chao Jung

AU - Lin, Chih Ying

AU - Wu, Yi Fang

AU - Li, Te Mao

AU - Chuang, Po Heng

AU - Wu, Yang Chang

AU - Lai, Chih Ho

AU - Liu, Xiang

AU - Tsang, Hsinyi

AU - Lin, Ting Hsu

AU - Liao, Chiu Chu

AU - Huang, Shao Mei

AU - Li, Ju Pi

AU - Lin, Jung Chun

AU - Lin, Chih Chien

AU - Liang, Wen Miin

AU - Lin, Ying Ju

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Chinese herbal medicine (CHM) is a complementary natural medicine that is used widely for the treatment of hepatic diseases. The aim of this study was to investigate the effects of the long-term use of CHM for the treatment of liver diseases, as prescribed by TCM doctors, on overall mortality and hepatic outcomes in patients with HCV. Patients and methods: We identified 98788 patients with HCV. Of these, 829 and 829 patients who were users and non-users of CHM, respectively, were matched for age, gender, CCI, and comorbidities prior to CHM treatment. The chi-squared test, Cox proportional hazard model, Kaplan–Meier method, and log-rank test were used for comparisons. Results: CHM users had a lower risk of overall mortality than non-users after adjustment for comorbidities by using a multivariate Cox proportional hazard model (p-value < 0.001; HR: 0.12, 95% CI: 0.06–0.26). In addition,the CHM users had a lower risk of liver cirrhosis than non-users after adjustment for comorbidities (p-value = 0.028; HR: 0.29, 95% CI: 0.09–0.88). The 12-year cumulative incidences of overall mortality and liver cirrhosis were lower in the CHM group (p-value < 0.05 for both, log rank test). The CHM co-prescription for Dan-Shen, Bie-Jia, Jia-Wei-Xiao-Yao-San => E-Shu was found to occur most often associated for the specific treatment of HCV infection. Conclusion: CHM as adjunctive therapy may reduce the overall mortality and the risk of liver cirrhosis in patients with HCV. The comprehensive list of the herbal medicines that may be used for the treatment of patients with HCV may be useful in future scientific investigations or for future therapeutic interventions to prevent negative hepatic outcomes in patients with HCV.

AB - Background: Chinese herbal medicine (CHM) is a complementary natural medicine that is used widely for the treatment of hepatic diseases. The aim of this study was to investigate the effects of the long-term use of CHM for the treatment of liver diseases, as prescribed by TCM doctors, on overall mortality and hepatic outcomes in patients with HCV. Patients and methods: We identified 98788 patients with HCV. Of these, 829 and 829 patients who were users and non-users of CHM, respectively, were matched for age, gender, CCI, and comorbidities prior to CHM treatment. The chi-squared test, Cox proportional hazard model, Kaplan–Meier method, and log-rank test were used for comparisons. Results: CHM users had a lower risk of overall mortality than non-users after adjustment for comorbidities by using a multivariate Cox proportional hazard model (p-value < 0.001; HR: 0.12, 95% CI: 0.06–0.26). In addition,the CHM users had a lower risk of liver cirrhosis than non-users after adjustment for comorbidities (p-value = 0.028; HR: 0.29, 95% CI: 0.09–0.88). The 12-year cumulative incidences of overall mortality and liver cirrhosis were lower in the CHM group (p-value < 0.05 for both, log rank test). The CHM co-prescription for Dan-Shen, Bie-Jia, Jia-Wei-Xiao-Yao-San => E-Shu was found to occur most often associated for the specific treatment of HCV infection. Conclusion: CHM as adjunctive therapy may reduce the overall mortality and the risk of liver cirrhosis in patients with HCV. The comprehensive list of the herbal medicines that may be used for the treatment of patients with HCV may be useful in future scientific investigations or for future therapeutic interventions to prevent negative hepatic outcomes in patients with HCV.

KW - Chinese herbal medicine

KW - HCV

KW - Liver cirrhosis

KW - Overall mortality

UR - http://www.scopus.com/inward/record.url?scp=85057316458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057316458&partnerID=8YFLogxK

U2 - 10.1016/j.phymed.2018.09.237

DO - 10.1016/j.phymed.2018.09.237

M3 - Article

AN - SCOPUS:85057316458

VL - 57

SP - 30

EP - 38

JO - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

ER -